Need professional-grade analysis? Visit stockanalysis.com
$45.40M
N/A
N/A
N/A
Kezar Life Sciences Inc (KZR) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $7.29, up 0.21% from the previous close.
Over the past year, KZR has traded between a low of $3.59 and a high of $7.43. The stock has gained 53.6% over this period. It is currently 103.2% above its 52-week low.
Kezar Life Sciences Inc has a market capitalization of $45.40M.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Side-by-side comparison against top Healthcare peers.